Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY

v3.10.0.1
CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total Shareholders Equity [Member]
Noncontrolling Interest [Member]
Total
BALANCE at Oct. 31, 2016 $ 14,000 $ 87,524 $ 152,051,144 $ (151,165,193) $ 987,475 $ 987,475
BALANCE (in Shares) at Oct. 31, 2016 140 8,752,387          
Stock option compensation to employees and directors     1,219,468   1,219,468   1,219,468
Stock options and warrants issued to consultants     3,304   3,304   3,304
Common stock issued upon exercise of stock options   $ 402 6,871   7,273   7,273
Common stock issued upon exercise of stock options (in Shares)   40,220          
Stock award compensation to directors and employee pursuant to stock incentive plan   $ 2,000 452,000   454,000   454,000
Stock award compensation to directors and employee pursuant to stock incentive plan (in Shares)   200,000          
Common stock issued to consultants   $ 95 32,329   32,424   32,424
Common stock issued to consultants (in Shares)   9,463          
Redemption of convertible preferred stock $ (14,000)   (3,486,000)   (3,500,000)   (3,500,000)
Redemption of convertible preferred stock (in Shares) (140)            
Common stock issued to repay patent acquisition obligation   $ 9,476 2,842,818   2,852,294   2,852,294
Common stock issued to repay patent acquisition obligation (in Shares)   947,606          
Common stock issued in shareholder rights offering   $ 19,892 4,183,410   4,203,302   4,203,302
Common stock issued in shareholder rights offering (in Shares)   1,989,207          
Common stock issued in registered direct offering   $ 34,254 3,177,534   3,211,788   3,211,788
Common stock issued in registered direct offering (in Shares)   3,425,376          
Common stock issued in at-the-market offering   $ 12,385 3,448,201   3,460,586   3,460,586
Common stock issued in at-the-market offering (in Shares)   1,238,500          
Net Loss       (5,008,991) (5,008,991)   (5,008,991)
BALANCE at Oct. 31, 2017 $ 166,028 163,931,079 (156,174,184) 7,922,923 7,922,923
BALANCE (in Shares) at Oct. 31, 2017 16,602,759          
Stock option compensation to employees and directors     5,717,651   5,717,651   5,717,651
Stock options and warrants issued to consultants     318,139   318,139   318,139
Common stock issued upon exercise of stock options   $ 766 57,372   58,138   58,138
Common stock issued upon exercise of stock options (in Shares)   76,636          
Stock award compensation to directors and employee pursuant to stock incentive plan   $ 15,000 2,844,824   2,859,824   2,859,824
Stock award compensation to directors and employee pursuant to stock incentive plan (in Shares)   1,500,000          
Common stock issued to consultants   $ 53 14,949   15,002   15,002
Common stock issued to consultants (in Shares)   5,347          
Common stock issued in at-the-market offering   $ 7,239 2,462,943   2,470,182   2,470,182
Common stock issued in at-the-market offering (in Shares)   723,890          
Issuance of noncontrolling interest in Certainty Therapeutics, Inc.     68,974   68,974 (4,318) 64,656
Net Loss       (13,996,025) (13,996,025) (247,059) (14,243,084)
BALANCE at Oct. 31, 2018 $ 189,086 $ 175,415,931 $ (170,170,209) $ 5,434,808 $ (251,377) $ 5,183,431
BALANCE (in Shares) at Oct. 31, 2018 18,908,632